Similarly, high expression levels of ANRIL [166], HOXB-AS1 [167], HOXC13-AS [168], DDX11-AS1 [169], ELF3-AS1 [170], FOXP4-AS1 [171], PITPNA-AS1 [172], MAFG-AS1 [173], ROR1-AS1 [174], and ZFAS1 [175], as well as the downregulation of ZNF385D-AS2 [176], have been variably shown to be correlated with pathological features and clinical outcome as survival and response to pharmacological treatment of HCC patients (Table 2). The gene discussed is PTGDR; the disease is hepatocellular carcinoma.